Biological barriers to therapy with antisense and siRNA oligonucleotides.
Attaining the full therapeutic utility of antisense and siRNA oligonucleotides will require understanding of the biological barriers that stand between initial administration of these drugs and their final actions within cells. This review examines some of the key barriers that affect the biodistribution of oligonucleotides both in molecular form and when they are associated with nanocarriers. An understanding of the biological processes underlying these barriers will aid in the design of more effective delivery systems.
Juliano
R
R
UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA. arjay@med.unc.edu
Bauman
J
J
Kang
H
H
Ming
X
X
D000818:Animals; D001692:Biological Transport; D004727:Endothelium / Q000378:metabolism; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage* / Q000493:pharmacokinetics; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000493:pharmacokinetics
D016376:Oligonucleotides, Antisense; D034741:RNA, Small Interfering